한국식품영양과학회지 (Journal of the Korean Society of Food Science and Nutrition)

  • 제40권9호
  • /
  • Pages.1201-1207
  • /
  • 2011
  • /
  • 1226-3311(pISSN)
  • /
  • 2288-5978(eISSN)
한국식품영양과학회 (The Korean Society of Food Science and Nutrition)
권호 표지
DOI QR코드

DOI QR Code

Genistein과 TRAIL의 복합처리에 의한 U937 인체 혈구암 세포의 Apoptosis 유도

Induction of Apoptosis by Combined-treatment with Genistein and TRAIL in U937 Human Leukemia Cells

  • 최영현 (동의대학교 한의과대학 생화학교실, 대학원 바이오물질제어학과(BK21 program) 및 블루바이오소재개발센터) ;
  • 한민호 (동의대학교 한의과대학 생화학교실, 대학원 바이오물질제어학과(BK21 program) 및 블루바이오소재개발센터)
  • Choi, Yung-Hyun (Department of Biochemistry, College of Oriental Medicine, Department of Biomaterial Control (BK21 Program), Graduate School, Blue-Bio Industry Regional Innovation Center, Dongeui University) ;
  • Han, Min-Ho (Department of Biochemistry, College of Oriental Medicine, Department of Biomaterial Control (BK21 Program), Graduate School, Blue-Bio Industry Regional Innovation Center, Dongeui University)
  • 투고 : 2011.06.30
  • 심사 : 2011.08.02
  • 발행 : 2011.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

TRAIL은 최근 암세포의 apoptosis 유도를 위한 효율적인 도구로 제시되었으나 많은 암세포들이 TRAIL 저항성을 획득한 것으로 알려져 TRAIL 저항성 극복을 위한 새로운 방법론의 제시가 요구되어지고 있다. Genistein은 대두의 대표적인 생리활성 물질인 isoflavonoid의 일종으로 많은 암세포에서 G2/M arrest를 유발하면서 apoptosis를 유도하는 것으로 알려져 있다. 본 연구에서는 U937 인체백혈병세포를 대상으로 genistein에 의한 TRAIL 유도 apoptosis의 감수성 증대 여부를 조사하였다. 본 연구의 결과에 의하면 U937 세포에서 세포독성이 없는 범위의 genistein 처리는 TRAIL에 의한 apoptosis 유도를 매우 증진시켰으며, 이는 tBid의 발현 증가와 cFLIPL의 발현 감소와 연계된 caspase의 활성 증가와 연관성이 있었다. 또한 caspase의 활성 저해제는 genistein과 TRAIL의 복합처리에 의한 apoptosis를 유의적으로 감소시켜 복합 처리에 의한 apoptosis의 유도에 caspase의 활성 증대가 필수적임을 알 수 있었다. 따라서 genistein은 TRAIL 저항성을 획득한 암세포의 효율적인 combined therapy approach를 위해 유용하게 사용될 수 있음을 알 수 있었다.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been proposed as a potent tool to trigger apoptosis in cancer therapy. However, as many types of cancer cells remain resistant towards TRAIL-induced cytotoxicity, several combined therapy approaches aimed to sensitize cells to TRAIL have been developed. Genistein, a natural isoflavonoid phytoestrogen, has been shown to have anticancer activity by inducing cell cycle arrest at G2M phase as well as apoptosis in various cancer cell lines. In the present study, we showed that treatment with TRAIL in combination with subtoxic concentrations of genistein sensitized U937 human leukemia cells to TRAIL-mediated apoptosis. Combined treatment with genistein and TRAIL effectively activated caspases through Bid truncation (tBid) and down-regulation of cellular caspase-8 (FLICE)-like inhibitory proteinL ($cFLIP_L$). However, the apoptotic effects of co-treatment with genistein and TRAIL were significantly inhibited by specific caspase inhibitors, which demonstrates the important role of caspases in apoptosis induced by genistein and TRAIL. Overall, our results indicate that genistein can potentiate TRAIL-induced apoptosis through down-regulation of $cFLIP_L$ and up-regulation of pro-apoptotic tBid proteins.

키워드

참고문헌

  1. Gilliland DG, Jordan CT, Felix CA. 2004. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004: 80-97. https://doi.org/10.1182/asheducation-2004.1.80
  2. Abramson N, Melton B. 2000. Leukocytosis: basics of clinical assessment. Am Fam Physician 62: 2053-2060.
  3. Wiernik PH. 1988. Leukemias and myeloma. Cancer Chemother Biol Response Modif 10: 129-147.
  4. Wang S, EI-Deiry SW. 2003. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633. https://doi.org/10.1038/sj.onc.1207232
  5. French LE, Tschopp J. 1999. The TRAIL to selective tumor death. Nat Med 5: 146-147. https://doi.org/10.1038/5505
  6. Srivastava RK. 2001. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3: 535-546. https://doi.org/10.1038/sj.neo.7900203
  7. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. 1999. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753.
  8. Aggarwal B, Shishodia S. 2006. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421. https://doi.org/10.1016/j.bcp.2006.02.009
  9. Sarkar FH, Adsule S, Padhye S, Kulkarni S, Li Y. 2006. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem 6: 401-407. https://doi.org/10.2174/138955706776361439
  10. Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV. 2006. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 66: 1136-1143. https://doi.org/10.1002/pros.20440
  11. Nozawa F, Itami A, SarucM, Kim M, Standop J, Picha KS, Cowan KH, Pour PM. 2004. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and genistein is effective in inhibiting pancreatic cancer growth. Pancreas 29: 45-52. https://doi.org/10.1097/00006676-200407000-00055
  12. Park SY, Seol DW. 2002. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 295: 515-518. https://doi.org/10.1016/S0006-291X(02)00719-2
  13. Jin CY, Park C, Cheong J, Choi BT, Lee TH, Lee JD, Lee WH, Kim GY, Ryu CH, Choi YH. 2007. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett 257: 56-64. https://doi.org/10.1016/j.canlet.2007.06.019
  14. Szliszka E, Czuba ZP, Jernas K, Król W. 2008. Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Mol Sci 9: 56-64. https://doi.org/10.3390/ijms9010056
  15. Bronikowska J, Szliszka E, Czuba ZP, Zwolinski D, Szmydki D, Krol W. 2010. The combination of TRAIL and isoflavones enhances apoptosis in cancer cells. Molecules 15: 2000-2015. https://doi.org/10.3390/molecules15032000
  16. Jin CY, Park C, Kim GY, Lee SJ, Kim WJ, Choi YH. 2009. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact 180: 143-150. https://doi.org/10.1016/j.cbi.2009.03.020
  17. Jin CY, Park C, Moon SK, Kim GY, Kwon TK, Lee SJ, Kim WJ, Choi YH. 2009. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs 20: 713-722. https://doi.org/10.1097/CAD.0b013e32832e8998
  18. Siegelin MD, Siegelin Y, Habel A, Gaiser T. 2009. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis. Neurosci Lett 453: 92-97. https://doi.org/10.1016/j.neulet.2009.02.018
  19. Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH. 1998. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 31: 184-191. https://doi.org/10.1080/01635589809514701
  20. Choi YH, Lee WH, Park KY, Zhang L. 2000. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 91: 164-173. https://doi.org/10.1111/j.1349-7006.2000.tb00928.x
  21. Choi YH, Zhang L, Lee WH, Park KY. 1998. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int J Oncol 13: 391-396.
  22. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG. 2006. Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6: 107. https://doi.org/10.1186/1471-2407-6-107
  23. Ouyang G, Yao L, Ruan K, Song G, Mao Y, Bao S. 2009. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways. Cell Biol Int 33: 1237-1244. https://doi.org/10.1016/j.cellbi.2009.08.011
  24. Zhao R, Xiang N, Domann FE, Zhong W. 2009. Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr Cancer 61: 397-407. https://doi.org/10.1080/01635580802582751
  25. Zhang L, Fang B. 2005. Mechanisms of resistance to TRAIL induced apoptosis in cancer. Cancer Gene Ther 12: 228-237. https://doi.org/10.1038/sj.cgt.7700792
  26. Yang LQ, Fang DC, Wang QR, Yang SM. 2004. Effect of NF-kB, survivin, Bcl-2 and caspase-3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol 10: 22-25. https://doi.org/10.3748/wjg.v10.i1.22
  27. Harris P, Ralph P. 1985. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leukoc Biol 37: 407-422. https://doi.org/10.1002/jlb.37.4.407
  28. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM. 1999. Yama/CPP32 $\beta$, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809.
  29. Griffith TS, Lynch DH. 1998. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563. https://doi.org/10.1016/S0952-7915(98)80224-0
  30. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. 2007. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475. https://doi.org/10.1016/j.biocel.2007.02.007

피인용 문헌

  1. TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies vol.98, pp.None, 2011, https://doi.org/10.1016/j.biopha.2017.12.082